Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab. (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s5. https://doi.org/10.25251/skin.1.supp.4